MTHFR-1298 A>C (rs1801131) is a predictor of survival in two cohorts of stage II/III colorectal canc...
MTHFR-1298 A>C (rs1801131) is a predictor of survival in two cohorts of stage II/III colorectal cancer patients treated with adjuvant fluoropyrimidine chemotherapy with or without oxaliplatin
About this item
Full title
Author / Creator
Cecchin, E , Perrone, G , Nobili, S , Polesel, J , De Mattia, E , Zanusso, C , Petreni, P , Lonardi, S , Pella, N , D'Andrea, M , Errante, D , Rizzolio, F , Mazzei, T , Landini, I , Mini, E and Toffoli, G
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Adjuvant treatment based on fluoropyrimidines (FL) improves the prognosis of stage II/III colorectal cancer (CRC). Validated predictive/prognostic biomarkers would spare therapy-related morbidity in patients with a good prognosis. We compared the impact of a set of 22 FL-related polymorphisms with the prognosis of two cohorts of CRC patients treate...
Alternative Titles
Full title
MTHFR-1298 A>C (rs1801131) is a predictor of survival in two cohorts of stage II/III colorectal cancer patients treated with adjuvant fluoropyrimidine chemotherapy with or without oxaliplatin
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1683352828
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1683352828
Other Identifiers
ISSN
1470-269X
E-ISSN
1473-1150
DOI
10.1038/tpj.2014.64
